Retinitis Pigmentosa

Beacon shines a light on positive early data from eye disease ph. 2

The company's gene therapy made for improvements in visual function for patients with X-linked retinitis pigmentosa at six months in its phase 2 study.

Zoey Becker May 7, 2025 7:15am

J&J gene therapy fails ph. 3 rare eye disease trial

May 5, 2025 11:33am

NIH creates eye drops that protect mice from vision loss

Mar 25, 2025 3:10pm

gift give present christmas package holidays

MeiraGTx gifts last of gene therapy rights to J&J for $415M

Dec 21, 2023 10:14am

ProQR, Théa ink new pact for eye assets after old one collapsed

Dec 8, 2023 11:01am

Nanoscope's gene therapy boosts vision function in phase 2 test

Mar 30, 2023 11:04am